Snake Venom Level Findings To Be Presented At IVECCS
14 years ago
2553 views
Posted
31st August, 2011 20h04
BioVeteria Life Sciences, LLC (BioVeteria) will present their venom level findings at the 2011 International Veterinary Emergency and Critical Care Conference. The abstract, entitled “Neutralizing effects of F(ab’)
2 antivenom on serum pit viper venom levels in dogs”, will be presented by Dr. Karen Seibold, a Diplomate of the American College of Veterinary Emergency and Critical Care.
The study evaluated the level of circulating venom in 55 dogs before and after treatment with a F(ab’)
2 snake antivenom. Serum samples were collected at various clinics in Texas, Arizona, Florida and California. Serum venom levels were evaluated before antivenom administration and then at 3, 6, 12 and 24 hours after F(ab’)
2 antivenom administration. The findings showed that administration of the F(ab’)
2 pit viper antivenom resulted in an immediate and prolonged drop of venom levels. Results were highly significant and are being prepared for submission to a peer-reviewed publication.
About F(ab’)2 antivenoms
BioVeteria produces antivenoms using antibody fragments, called “Fragment antigen binding (Fab) dimers”, or “F(ab’)
2”. BioVeteria’s F(ab’)
2 antivenom has been previously shown to neutralize all common North American pit viper venoms, and consists of F(ab’)
2 antibody fragments, which makes it properties different from whole IgG and Fab antivenoms. BioVeteria’s F(ab’)
2 pit viper antivenom has broad neutralizing properties against all common North American pit vipers.
About BioVeteria Life Sciences, LLC
BioVeteria is a privately held bioscience company that is developing a range of new products for veterinary medicine, including F(ab’)
2 antivenoms, optimized nutraceuticals, diagnostics and devices for veterinary applications. Located in historic Prescott, Arizona, BioVeteria is dedicated to advancing clinically meaningful technology for dogs, cats, and horses.
More from
